Davunetide (Allon Therapeutics) fails trial for Supranuclear Palsy

Allon Therapeutics Inc. has announced that its pivotal clinical trial evaluating its lead product candidate davunetide as a treatment for progressive supranuclear palsy (PSP) failed to demonstrate efficacy in this population. The study had co-primary outcome measures: the Progressive Supranuclear Palsy Rating Scale (PSPRS), and the Schwab and England Activities of Daily Living (SEADL). Data analysis failed to detect an effect on either the PSPRS or the SEADL.The Company will undertake further analysis to determine if there is any evidence of an effect or explanation for the absence of an effect.